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Abstract
Objective: To immunophenotype CD4+ and CD8+ T cell sub-populations in HIV-associated immune reconstitution
inflammatory syndrome (IRIS).
Design: Nested case-control immunological study.
Methods: ART-naïve HIV-infected patients were prospectively observed for IRIS during the first 6 months of ART.
Twenty-two IRIS cases and 22 ART-duration matched controls were sampled for T cell immunophenotyping.
Results: IRIS cases demonstrated significantly lower CD4 cell counts compared to controls (baseline: 79 versus 142, p
= 0.02; enrollment: 183 versus 263, p = 0.05, respectively) with no differences in HIV RNA levels. Within CD4+T cells,
cases exhibited more of an effector memory phenotype compared to controls (40.8 versus 27.0%, p = 0.20), while
controls trended towards a central memory phenotype (43.8 versus 30.8%, p = 0.07). Within CD8+ T cells, controls
exhibited more central memory (13.9 versus 7.81%, p = 0.01, respectively) and effector (13.2 versus 8.8%, p = 0.04,
respectively) phenotypes compared to cases, whereas cases demonstrated more terminal effectors than controls (28.8
versus 15.1%, p = 0.05). Cases demonstrated increased activation of CD8+ T cell effector memory, terminal effector, and
effector subsets than controls (p = 0.04, 0.02, and 0.02, respectively).
Conclusion:  CD4+ and CD8+ T cell subset maturational phenotypes were heterogeneous among IRIS cases and
controls. However, IRIS cases demonstrated significant increases in activation of CD8+ T cell effector subpopulations.
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Background
The immune reconstitution inflammatory syndrome
(IRIS) or immune reconstitution disease (IRD) is a clinical
deterioration occurring in the first few weeks following
the introduction of antiretroviral therapy (ART) [1,2]. This
clinical deterioration is due to immune restoration and a
subsequent inflammatory response to a wide variety of
intact subclinical pathogens and/or residual antigen[3].
Incidence estimates of the syndrome vary depending on
the population studied and case definitions used, but sug-
gest IRIS affects a significant proportion (10–32%) of
patients initiating ART [2,4-7].
It is speculated that IRIS results from the restoration of
immunity to pathogen-specific antigens present at the
time of ART initiation. Following ART, a quantitative
increase in peripheral T cells occurs which partially
restores activity to recall antigens as a result of suppression
of HIV viral replication in lymphoid tissue and reductions
in immune activation [8,9]. Furthermore, restoration of in
vitro  responses to common infectious antigens and
improvement in delayed type hypersensitivity has been
significantly associated with increases in memory CD4 T
cells following ART [10].
Although the immunopathogenesis of the syndrome
remains largely unknown, these observations have
resulted in the hypothesis that IRIS results, at least in part,
from the restoration of immunity to pathogen specific
antigens present at the time or ART initiation and from
redistribution of antigen-specific memory T cells with tis-
sue-specific localized inflammation [3,11]. This theory is
further supported by the observation of an exuberant pro-
inflammatory Th1 response to mycobacterial antigens in
IRIS patients independent of the degree of absolute CD4
cell recovery [12]. To date, studies have suggested a pre-
dominance of memory phenotype CD4+ cells in localized
inflammatory tissue [11]. However, these results are diffi-
cult to interpret given the lymphocyte redistribution fol-
lowing ART in all HIV-infected subjects and the lack of
non-IRIS patients for comparison.
In order to test the hypothesis that IRIS results, in part,
from the peripheral redistribution of a greater number of
T cells with a predominant memory phenotype, we per-
formed immunophenotyping to characterize T cell popu-
lations in IRIS and non-IRIS subjects. We also examined
differences in immune activation between groups in an




Participants consisted of confirmed IRIS cases and con-
trols selected from an HIV-infected ART-naïve adult (>18
years) cohort who participated in a prospective surveil-
lance study to examine the incidence of IRIS in Sub-Saha-
ran Africa between January 6, 2006 and July 7, 2007 [5].
ART initiation criteria were in accordance with the South
Africa National ART Program and included a CD4 count
≤200 cells/mm3 or WHO stage IV AIDS-defining illness
irrespective of CD4 count. Patients received scheduled
clinical assessments, including at least one pre-treatment
assessment, one treatment commencement assessment,
and regularly scheduled assessments at weeks 2, 4, 8 and
every 3 months thereafter [13]. Enrollment into the
nested case-control study required participation in the
prospective surveillance cohort, a pre-treatment CD4
count and HIV RNA level, and willingness to provide writ-
ten informed consent for an additional blood draw and
sample storage.
In general, IRIS is clinically defined as a paradoxical clini-
cal worsening due to a subclinical opportunistic pathogen
("unmasking" IRIS) or previously known treated (com-
pleted or ongoing) opportunistic pathogen ("paradoxi-
cal" IRIS) in the setting of an adequate response to ART
[14-16]. For the "unmasking" form of IRIS, a new local-
ized infection was required from a focal inflammatory
process (suppurative lymph node, pulmonary infiltrate,
positive CSF culture, etc.) in a patient who, prior to ART,
exhibited no signs or symptoms of disease and in whom
adequate OI screening and clinical assessment had been
performed (i.e. negative pre-ART sputum AFBs in the case
of "unmasking" pulmonary TB). For organisms for which
cultures or diagnostic studies were available (i.e. TB, Cryp-
tococcus) demonstration of the organism or a pathologi-
cal process characteristic of the organism (i.e. caseous
necrosis, granulomatous inflammation) were required.
For the "paradoxical" form of IRIS, a patient required the
diagnosis and treatment initiation of an OI prior to ART
initiation with a positive clinical response. Following
ART, the patient experienced a new inflammatory process
(worsening lymphadenopathy or suppuration, expansion
of Kaposi's lesions, recurrence of meningeal signs and
symptoms) at the original or new site of infection accom-
panied by systemic symptoms (fever, loss of weight, ele-
vated white blood cell count). For all cases, no other
identifiable pathogen could be present after thorough
diagnostic evaluation.
For this immunological analysis, only confirmed IRIS cases
were examined. These consisted of subjects who: 1) exhib-
ited symptoms consistent with an infectious or inflamma-
tory condition while on ART which could not be
explained by the expected clinical course of a previously
recognized infectious agent or by side effects of therapy,
and 2) whose treatment led to a ≥1 log10 drop in HIV RNA
at time of IRIS diagnosis, and 3) whose treatment resulted
in adequate immune reconstitution 6 months post ART,AIDS Research and Therapy 2009, 6:16 http://www.aidsrestherapy.com/content/6/1/16
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defined as a ≥1 log10 drop in HIV RNA or a CD4 count
equal to or above the pre-treatment baseline value.
Peripheral blood sampling was performed at the time of
IRIS diagnosis for IRIS cases and at study enrollment for
matched controls. Eligible control subjects were matched
on ART duration within ± 2 weeks in a 1:1 ratio. The study
protocol was reviewed and approved by all participating
institutional review boards.
CD4 cell count and HIV RNA level measurements
Longitudinal CD4 and CD8 cell counts were measured as
previously described [17]. Plasma samples were assayed
for HIV-1 RNA levels using the Amplicor polymerase-
chain reaction test (Roche Diagnostics, Switzerland).
Cell isolation, storage, and thawing
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from sodium heparin anticoagulated human blood
by density centrifugation (Histopaque, Sigma, Germany).
PBMCs were harvested, washed using Hanks Balanced Salt
Solution (H9394, Sigma, Germany), and centrifuged at
400 g for 10 minutes. PBMCs were then resuspended in
Hanks Balanced Salt Solution and counted using an auto-
mated cell counter (Guava Technologies, USA). After
counting, 10 million PBMCs/ml were cryopreserved using
1 ml of 10% Dimethyl Sulfoxide (Sigma, Germany) and
90% Fecal Calf Serum (Sigma, Germany) cryopreserva-
tion solution. Samples were rate-controlled frozen to -
80°C, stored overnight, and then transferred into liquid
nitrogen at -180°C until analysis.
Culture medium (R10) was prepared by adding HEPES
buffer (1 M), penicillin-streptomycin (1%), sodium pyru-
vate (100 mM), L-glutamine (200 mM) and heat-inacti-
vated fetal bovine serum (10%) (Sigma, USA) to RPMI
1640 medium (Sigma, Germany). PBMC vials were
thawed in a 37°C water bath and 1 ml of R10 with 50 U/
ml benzonase (Novagen, Denmark) was added, after
which cells were resuspended to 8 ml using R10. Cells
were centrifuged for 10 minutes at 250 g, resuspended
and washed again using R10. Cells were then counted
(Guava Technologies, USA) and rested overnight in a
37°C 5% CO2 atmosphere.
Cell surface staining and measurements
Following overnight rest, 1.0–2.0 × 106 viable PBMC were
stained as previously described[18] using the following
optimally titrated monoclonal antibody conjugates in a
single tube 9-color panel: HLA-DR APC-Cy7 (L243);
CD38 PE Quantibrite (HB7); CD8 Alexa700 (RPA-T8);
CD27 APC (L128); CD57 FITC (HNK-1); CD3 AmCyan
(SK7); CD4 PerCP Cy5.5 (SK3) (BD Biosciences, CA,
USA); CD45RO ECD (UCHL1, Beckman Coulter, France)
and vAmine (LIVE/DEAD® Fixable Violet Dead Cell Stain,
Invitrogen, USA). An additional 9-color tube consisted of
isotype controls for HLA-DR and CD38 using mouse IgG1
APC-Cy7 isotype (X40) and mouse IgG1 PE isotype (X40)
(BD Biosciences, USA).
All data were immediately acquired using an LSRII flow
cytometer (BD Biosciences, USA) within 4 hours of stain-
ing. Between 500,000 and 2 million events were acquired
per sample. Compensation was performed daily digitally
using FACSDiva software (version 5.0, BD Biosciences,
USA) by staining compensation beads (anti-mouse Igκ,
BD Biosciences, USA) with the antibodies described with
the exception of vAmine which was substituted with
CD14 Pacific Blue (BD Biosciences, USA). PMT voltages
were checked daily through gating of peak 8 beads (Sphe-
rotech, Il, USA). CD38 PE quantitation was performed
using CD38 PE Quantibrite and Quantibrite PE Beads
(BD Biosciences, USA) according to manufacturer recom-
mended procedures [19].
List mode data were analyzed with FlowJo v8.5 (Treestar).
Initial singlet gating used a forward scatter width (FSC-W)
versus height (FSC-H) plot. Events were then gated
through a CD3+ versus vAmine to identify a minimum of
10,000 viable CD3+ lymphocytes and sequentially gated
on CD4+ and CD8+ populations. Maturational subsets
were defined for CD4+ and CD8+ populations as follows:
naïve (N) (CD45RO-CD27+), central memory (CM)
(CD45RO+CD27+), effector memory (EM) (Effector
Memory; CD45RO+CD27-), E (Effector;
CD45RO+CD57+), & TE (Terminal Effector; CD45RO-
CD57+) [20,21]. Focusing on cells co-expressing CD38
and HLA-DR antigens, cellular activation was measured
quantitatively by the number of CD38 PE antibodies
bound per cell (ABC), which reflects the density of CD38
antigen on the surface of activated T cells [19]. Cellular
activation was measured for each respective CD4+ & CD8+
maturational subset. Figure 1 is an example of gating
methods employed for all samples.
Statistical analyses
Group comparison of baseline clinical and immunologi-
cal data were performed using the Wilcoxon rank sum and
Fisher's exact tests (Stata v10, College Station, USA),
where appropriate, with an a priori definition of <0.05
considered significant. Group comparisons (IRIS vs. non-
IRIS controls) of CD4+ and CD8+ T population subset per-
centages were performed using the Wilcoxon-Mann-Whit-
ney test. The activation markers CD38 and HLA-DR were
gated from CD4+ and CD8+ cells their subsets in which
quadrant gates, using an isotype control, were used to
define positive and negative populations. For the meas-
urement of CD38 PE ABCs, a minimum of 50 CD38+
HLA-DR+ events were required within each T cell popula-
tion maturational subset for statistical analysis.AIDS Research and Therapy 2009, 6:16 http://www.aidsrestherapy.com/content/6/1/16
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Results
Cohort characteristics and clinical outcomes
As reported previously [5], in brief, among the 423 obser-
vational cohort patients enrolled, 44 (10.4%) developed
IRIS. Clinical manifestations included TB (18/44, 41%),
cryptococcal meningitis (3/44, 6.8%), herpes simplex
infection (4/44, 9.1%), varicella zoster infection (6/44,
13.6%), molluscum contagiosum (3/44, 6.8%), and
Kaposi's sarcoma (2/44, 4.5%), and infectious dermato-
logical manifestations (8/44, 18.2%). With the exception
of cases being younger than controls (31 versus 38 years,
respectively, p = 0.02), baseline demographics and clinical
history were similar between groups (Table 1). The major-
ity (39/44, 89%) were initiated on stavudine/lamivudine/
efavirenz.
Immunovirologic outcomes
Of the 44 cases, 22 IRIS cases and 22 matched controls
met enrollment criteria for the immunological nested
case-control study. Reasons for failure to enroll in the
immunological study were prisoner status (n = 2), patient
refusal (n = 3), missing baseline or follow-up CD4 count
or viral load (n = 4), and failure to enroll patient within
two weeks of IRIS identification (n = 13). The median
interval of time between ART initiation and the develop-
ment of IRIS was 38 days (Interquartile range (IQR): 24,
56), with immunological sampling occurring one week
later after IRIS diagnosis and clinical evaluations were
complete (45 days, IQR: 27–59). Cases demonstrated sig-
nificantly lower baseline CD4 cell counts compared to
controls (79 versus 142 cells/mm3, respectively, p = 0.02)
with similar baseline HIV RNA levels (Table 1). This
observation persisted at IRIS diagnosis and control enroll-
ment (183 versus 263 cells/mm3, respectively, p = 0.05)
with a continued, but nonsignificant trend by after 6
months of ART (161 versus 277, respectively, p = 0.10).
Absolute and percentage changes in CD4 cell count at IRIS
diagnosis (for cases) or control enrollment (for matched
controls) and at 6 months follow-up were not significant
between cases or controls (data not shown). At IRIS diag-
T cell population maturation and activation profiles for an IRIS case and control subject Figure 1
T cell population maturation and activation profiles for an IRIS case and control subject. (A). The IRIS case dem-
onstrates greater proportions of CM, TE, and E CD8+ T cell maturational phenotypes compared to the control, which mani-
fests a predominate N and CM phenotype. (B). Differences in CD38 PE expression (activation) within EM, TE, and E subsets 
between an IRIS case (red line) and respective control (blue line). N: Naïve; CM: Central Memory; EM: Effector Memory; TE: 
Terminal Effector; E: Effector.AIDS Research and Therapy 2009, 6:16 http://www.aidsrestherapy.com/content/6/1/16
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nosis or control enrollment, controls demonstrated
higher absolute CD8 cell counts than cases (875 versus
578 cells/mm3, p = 0.02), but no difference in CD8 cell
percentage (57 versus 55%, p = 0.15) or CD4:CD8 cell
ratio (0.32 versus 0.28, p = 0.64). Response to ART was
similar between groups, with no differences in HIV RNA
levels at enrollment or at 6 months.
CD4 and CD8 T cell subset phenotyping
Of the 44 immunologic samples, 3 cases and their respec-
tive controls were excluded from flow cytometric analyses
secondary to poor cell viabilities and insufficient cell data.
Within CD4+ T cells, no significant differences in subset
percentages between cases and controls were observed
(Table 2). However, both cases and controls demon-
strated a predominant CD4+ memory phenotype. Cases
trended towards more of an effector memory (EM) phe-
notype compared to controls (40.8 versus 27.0%, p =
0.20), while controls demonstrated a trend towards an
increased central memory (CM) subset (43.8 versus 30.8,
p = 0.07).
Within CD8+ T cells, the overall percentage of CD8+ T cells
was similar between groups, but subset maturational pro-
files were heterogeneous. Controls again exhibited signif-
icantly higher percentages of central memory (CM)
compared to cases (13.9 versus 7.81%, p = 0.01) and
exhibited more of an effector (E) phenotype compared to
cases (13.2 versus 8.8%, p = 0.04). On the other hand,
cases demonstrated an increase in terminal effectors (TE)
compared to controls (28.8 versus 15.1%, p = 0.05).
CD4 and CD8 T cell activation profiles
T cell activation, as measured by the number of CD38 PE
ABCs on respective CD38+ HLA-DR+ T cell subsets, dem-
onstrated significant differences between IRIS cases and
Table 1: Demographic and longitudinal immunologic data for IRIS cases and matched controls
Characteristic* Controls (n = 22) Cases (n = 22) p-value±
Black race 22 (100) 22 (100) 0.99
Age (years), median (IQR) 38 (34, 47) 31 (29, 39) 0.02
Female sex 16 (73) 15 (68) 0.99
Duration since HIV diagnosis (months), median (IQR) 5.1 (2.7, 21.2) 2.7 (1.2, 26.8) 0.13
No. previous OI/HIV-related illnesses‡
0 4 (18) 8 (36) 0.23
1 10 (45) 8 (36)
2 5 (23) 6 (28)
3 3 (14) 0(0)
TB status at ART initiation
No history of TB 10 (46) 15 (68) 0.26
Therapy completed before ART initiation 6 (27) 2 (9)
Therapy ongoing at ART initiation 6 (27) 5 (23)
Baseline immunovirologic data
CD4 cell count 79 (17, 140) 142 (67, 198) 0.02
CD4 cell percentage 7.0 (3.4, 9.0) 7.2 (4.6, 13.6) 0.51
HIV RNA, log10 copies/ml 5.4 (4.6, 5.9) 5.4 (4.5, 5.9) 0.77
Immunovirologic data at IRIS diagnosis/control enrollment
CD4 cell count, cells/mm3§ 183 (66, 252) 263 (152, 337) 0.05
CD4 cell percentage 13.5 (10.4, 20) 14 (10.2, 20.4) 0.96
CD8 cell count, cells/mm3 578 (239, 1006) 875 (623, 1487) 0.02
CD8 cell percentage 55 (49, 57) 57 (50, 62) 0.15
CD4:CD8 cell ratio 0.28 (0.19, 0.39) 0.32 (0.14, 0.34) 0.64
HIV RNA, log10 copies/ml 2.6 (2.6, 2.7) 2.6 (2.6, 2.6) 0.42
Immunovirologic data at 6 months
CD4 cell count, cells/mm3§ 161 (99, 294) 277 (158, 372) 0.10
CD4 cell percentage 13.9 (9.8, 20.7) 13.7 (10.2, 21.0) 0.96
HIV RNA, log10 copies/ml 2.6 (1.6, 2.6) 2.3 (1.6, 2.6) 0.26
*Data are no. (%) of patients or medians (IQR), unless otherwise indicated. ± p-values for comparison of case/control groups using Wilcoxon rank 
sum and Fisher's exact tests, where appropriate; <0.05 considered significant.
‡As listed by the WHO (Reference number: WHO/HIV/2005.02). §Missing value for 1 IRIS case.AIDS Research and Therapy 2009, 6:16 http://www.aidsrestherapy.com/content/6/1/16
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matched controls (Figure 2). Within CD8+ subsets, but
not within CD4 subsets, cases tended to have more acti-
vated CD8+ T cells, demonstrating significantly higher lev-
els of activated effector memory (CD27-CD45RO+),
terminal effectors (CD57+CD45RO-), and effector
(CD57+CD45RO+) subsets (p = 0.04, 0.02, and 0.02,
respectively) and tended to have higher activation levels
of central memory subsets (CD27+CD45RO+) (p = 0.10).
Discussion
In one of the first attempts to prospectively examine the
immunopathogenesis of IRIS, we observed phenotypic
heterogeneity across maturational subsets of CD4+ and
CD8+ T cells. Interestingly, the surface density of CD38
antigen, a measure of cellular activation previously associ-
ated with HIV pathogenesis, was significantly elevated
among IRIS subjects. Specifically, IRIS subjects were char-
acterized by higher activation levels of all CD8+ effector
subsets (effector memory, terminal effector, and effector).
CD38 and HLA-DR cells surface markers are up regulated
upon antigenic stimulation and are used as markers of T
cell activation. Varying fluorescence intensity of CD38
expression has been documented in HIV-infected patients
prior to commencing therapy [22]. Additionally, CD38
antigen expression levels are correlated with HIV RNA lev-
els and beneficial responses to ART or relapses in therapy
[18,22-24]. Increased expression of HLA-DR and CD38
on CD4+ T cells has also been demonstrated in coinfected
HIV-infected patients compared to uninfected patients
[25]. Although our findings favored activation within
CD8+ T cells, these investigators noted similar trends in
the CD4+  population. Together with the finding of
increased expression of HLA-DR on CD4+  T cells in
patients experiencing TB-IRIS [12], our data suggest that T
cell activation markers may be indicative of an underlying
opportunistic infection and may prove a useful biomarker
for identifying patients with activated immune systems
and who are at risk for IRIS. Our observation of increases
in T cell activation markers in IRIS cases despite similar
HIV RNA levels between cases and controls may suggest
that immune activation is driven by other factors such as
coinfection in addition to HIV RNA levels. How coinfec-
tions act synergistically with HIV to drive immune activa-
tion and whether T cell activation markers are elevated at
baseline in IRIS patients versus non-IRIS patients remain
to be fully elucidated.
Increases in activation markers among effector CD8 T cell
populations may provide insight into the immunopatho-
genesis of IRIS. Effector CD8 T cells exhibit specialized
functions such as cytotoxicity, antiviral cytokine produc-
tion, telomerase activity [26,27] and production of
cytokines such as IL-2, IFN-γ, TNF-α, perforin, and
granzymes A/B/C/K [28,29]. Of these, IFN-γ is known to
be increased in response to mycobacterial antigens in
patients experiencing TB-IRIS [12,30]. Effector memory
cells localize predominately to inflamed non-lymphoid
and peripheral tissues where they exhibit immediate effec-
tor functions, while central memory T cells express CD62L
and CCR7 and localize to lymphoid tissues [31-33].
Because of their peripheral distribution and immediate
effector function, effector CD8 T cells may mediate imme-
diate but unsustained responses to peripheral antigens
[34,35]. Given that IRIS usually occurs within the first few
weeks after ART initiation in patients with lower CD4 cell
Table 2: Summary of CD4 and CD8 T lymphocyte subset percentages for 19 IRIS cases and 19 matched controls at the time of 
diagnosis (IRIS cases) or enrollment (controls matched on ART duration)
T cell subset Controls (n = 19) Cases (n = 19) p-value*
CD4 T lymphocytes±
CD4+ 21.8 (17.2 – 32.5) 21.0 (14.4 – 25.5) 0.38
CD27+ CD45RO- (N) 10.5 (8.44 – 25.3) 15.3 (3.07–25.8) 0.90
CD27+ CD45RO+ (CM) 43.8 (31.3–55.7) 30.8 (13.9 – 50.0) 0.07
CD27- CD45RO+ (EM) 27 (13.2 – 42.8) 40.8 (23.9 – 58.9) 0.20
CD57+ CD45RO- (TE) 0.37 (0.1 – 1.4) 0.38 (0.18 – 2.76) 0.58
CD57+ CD45RO+ (E) 3.99 (1.94 – 10.7) 6.03 (2.63 – 22) 0.17
CD8 T lymphocytes±
CD8+ 70.2 (60.1 – 77) 68.3 (60.5 – 77.4) 0.90
CD27+ CD45RO- (N) 13.3 (9.9 – 17.9) 18.5 (10.3 – 26.6) 0.23
CD27+ CD45RO+ (CM) 13.9 (10.4 – 22.6) 7.81 (3.46 – 12.7) 0.01
CD27- CD45RO+ (EM) 29 (22.7 – 36.1) 20.2 (9.0 – 31.7) 0.08
CD57+ CD45RO- (TE) 15.1 (12.1 – 30.8) 28.8 (18.0 – 42.0) 0.05
CD57+ CD45RO+ (E) 13.2 (7.6 – 24.5) 8.8 (5.5 – 10.7) 0.04
All values determined by manual gating as detailed in methods. All values expressed as median percentage (Interquartile Range) unless otherwise 
noted. * p-values for comparison of case/control groups using Wilcoxon rank sum test; <0.05 considered significant. ±N: Naïve; CM: Central 
Memory; EM: Effector Memory; TE: Terminal Effector; E: EffectorAIDS Research and Therapy 2009, 6:16 http://www.aidsrestherapy.com/content/6/1/16
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(A) CD4 T cell CD38 activation patterns between IRIS cases and matched controls Figure 2
(A) CD4 T cell CD38 activation patterns between IRIS cases and matched controls. Insufficient number of events 
for analysis of TE subset. (B) CD8 T cell CD38 activation patterns between IRIS cases and matched controls. *p-values for 
comparison of case/control groups using Wilcoxon rank sum test; <0.05 considered significant; ±N: Naïve; CM: Central Mem-
ory; EM: Effector Memory; TE: Terminal Effector; E: Effector.
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counts and often involves peripheral tissues such as the
lung, a very early and unregulated effector memory
response may play a pathogenic role in the syndrome.
The predominance of a CD4+ memory cell phenotype in
both cases and controls is in agreement with observations
of phenotypic profiles following initiation of ART [8,9].
Although it has been hypothesized that the immun-
opathogenesis of IRIS may lie within the CD4+ memory
cell population [11], we observed no significant pheno-
typic differences in the percentage of memory cell pheno-
types or their activation markers. This may have been due
to our limited sample size, peripheral blood compartment
sampling, and selection of HIV-infected patients with
CD4 cells counts <200 cells/mm3. Alternatively, this
observation supports the increasing opinion that the
manifestations of IRIS due to a variety of pathogens pos-
sess distinct immunopathological etiologies. Examples
include the role of cytotoxic CD8 T cells in cases of vari-
cella zoster virus IRIS and delayed-type hypersensitivity
(DTH) reactions in cases of mycobacterial IRIS [36,37]
The present study had a number of limitations. First, the
immunological phenotypes reported here span patients
presenting with a wide range of infectious causes of IRIS.
While the common cause of IRIS, regardless of the patho-
gen, may be due to restoration of an antigen-specific
response, the immunopathogenesis of specific forms of
IRIS, such as TB-IRIS, may be unique. Second, the diagno-
sis of IRIS is difficult. Although we used a strict definition
for IRIS requiring the use of HIV RNA to objectively verify
a positive response to ART, no gold standard definition or
immune marker to define IRIS presently exists. Third, as
with most immunological IRIS studies to date, ours was
limited to the analysis of peripheral blood mononuclear
cells with the assumption that the tissue-level immune
response in IRIS is similar to that observed in the periph-
eral blood compartment. Future tissue-level IRIS immu-
nology studies are needed, given others have
demonstrated that non-IRIS HIV-infected patients on ART
possess differences in immune activation patterns
between tissue and peripheral blood [8]. Lastly, despite
being one of the largest prospective immunological IRIS
studies to date, the limited sample size and the low
median CD4 cell count in our population may have lim-
ited our ability to examine immunological differences
within T cells subsets, particularly within CD4+ T lym-
phocyte subpopulations. Furthermore, this prospective
study examined immunological difference between sub-
jects after ART at the time of IRIS diagnosis and did not
match subjects on baseline CD4 count. Thus, whether a
difference in activation profiles exists between IRIS and
non-IRIS subjects with similar baseline HIV RNA levels
and CD4 cell counts remains to be determined.
In summary, in this prospective immunological study of
IRIS in Sub-Saharan Africa, we observed heterogeneous T
cell maturation among individuals experiencing IRIS and
ART-matched controls and significant increases in activa-
tion markers in CD8+ T cell effector subpopulations. These
findings may therefore be useful in the development of
future studies aimed at identifying patients at risk for the
development of IRIS. Future prospective pathogen-spe-
cific IRIS immunological studies will likely require collab-
orative approaches and include measurement of effector
CD8+ and CD4+ subpopulations, cytokine responses, and
activation profiles in order to increase our understanding
of its pathogenesis and identify potential biomarkers for
the disease.
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